secwatch.observer — SEC 8-K summary
======================================

Issuer:     10x Genomics, Inc. (TXG)
CIK:        0001770787
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001770787-25-000058
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

10x Genomics Q3 revenue $149M (-2% YoY); guides Q4 $154-158M
------------------------------------------------------------

- Revenue $149.0M in Q3 2025, down 2% YoY; gross margin 67% vs 70% prior year.
- Operating loss improved to $32.2M from $41.5M; net loss $27.5M vs $35.8M.
- Cash and marketable securities $482.1M, up $35M sequentially.
- Q4 2025 revenue guidance $154-158M (midpoint 6% decline YoY, 5% sequential growth).
- Launched next-gen Chromium Flex and Xenium Protein spatial multiomic workflow.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770787/000177078725000058/0001770787-25-000058-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770787/000177078725000058/txg-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001770787-25-000058

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer